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Synopsis 
This study shows how Hnf1b inactivation in pancreatic ductal cells leads to 
chronic pancreatitis, neoplasia and potentiates PanIN formation. This reveals a cause of 















 Background and aims. The exocrine pancreas consists of acinar cells that 
produce digestive enzymes transported to the intestine through a branched ductal 
epithelium. Chronic pancreatitis is characterized by progressive inflammation, fibrosis 
and loss of acinar tissue. These changes of the exocrine tissue are risk factors for 
pancreatic cancer. The cause of chronic pancreatitis cannot be identified in one-quarter 
of patients. Here, we investigated how duct dysfunction could contribute to pancreatitis 
development. 
 Methods. The transcription factor Hnf1b, first expressed in pancreatic 
progenitors, is strictly restricted to ductal cells from late embryogenesis. We have 
previously shown that Hnf1b is crucial for pancreas morphogenesis but its postnatal 
role still remains unelucidated. To investigate the role of pancreatic ducts in exocrine 
homeostasis, we inactivated Hnf1b gene in vivo in mouse ductal cells. 
 Results. We uncovered that postnatal Hnf1b inactivation in pancreatic 
ducts leads to chronic pancreatitis in adults. Hnf1b∆duct mutants display dilatation of 
ducts, loss of acinar cells, acinar-to-ductal metaplasia (ADM) and lipomatosis. We 
deciphered the early events involved, with downregulation of cystic disease-associated 
genes, loss of primary cilia, upregulation of signaling pathways, especially Yap pathway 
involved in ADM. Remarkably, Hnf1b∆duct mutants developed pancreatic intraepithelial 
neoplasia and promote PanIN progression in concert with KRAS. We further showed 
that adult Hnf1b inactivation in pancreatic ducts is associated with impaired 
regeneration after injury, with persistent metaplasia and initiation of neoplasia. 
 Conclusion. Loss of Hnf1b in ductal cells leads to chronic pancreatitis and 

































Pancreatitis is a common disorder with significant morbidity and mortality, yet 
little is known about its pathogenesis, and there is no specific or effective treatment. It is 
characterized by progressive inflammation, necrosis/apoptosis, fibrosis, loss of acinar 
tissue and acinar-to-ductal metaplasia (ADM). Chronic pancreatitis increases the risk of 
pancreatic cancer 1. Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal 
malignancies in humans, occurring through the progression of precursor lesions, the 
best described being pancreatic intraepithelial neoplasia (PanIN). ADM is critical in 
neoplastic transformation, since metaplastic acinar cells can undergo the 
reprogramming process from ADM to form PanINs 2,3. Fibrosis also provides the 
background for PanIN development 4. 
The major etiologies of pancreatitis are obstruction of the pancreatic duct usually 
due to gallstones, alcohol, and smoking. Pancreatitis has also been associated with 
genetic factors, including mutations of cystic fibrosis transmembrane regulator (CFTR) 
gene, as well as PRSS1, SPINK-1, CTRC, CLDN2. However, the cause of chronic 
pancreatitis cannot be identified in about 30% of patients 4. 
The exocrine compartment of the pancreas consists of acinar cells that secrete 
enzymes and an intricate system of epithelial ductal cells that secrete the fluid carrying 
the digestive enzymes in the gut. Ductal cells comprise centroacinar cells, intercalated 
intralobular and interlobular ducts, linking the acinar lobules to the main pancreatic 
duct that drains into the duodenum 5. In vertebrates, pancreatic duct morphogenesis 
initiates with the formation of a network of primitive ducts, which matures into a 
tubular system. A restricted set of transcription factors are involved in ductal cell 














cells harbor an immotile primary cilium 7–9. These microtubule-based organelles 
projecting from the surface of the pancreatic ductal cells function as chemo- and 
mechano-sensors and integrate multiple signaling pathways 10. Except for duct 
obstruction and mutations in CFTR gene, duct contribution in acinar cell homeostasis is 
poorly known and the cellular and molecular mechanisms leading to acinar damage and 
chronic pancreatitis are poorly understood. 
In the present study, we investigate how duct dysfunction may contribute to 
pancreatitis. We focused on the transcription factor Hnf1b, which presents a very 
interesting profile. It is first expressed in pancreatic progenitors, then restricted to 
ductal cells from late embryogenesis such as only few transcription factors, and so not 
expressed in acinar cells 11–13. We have previously shown that Hnf1b is crucial for duct 
morphogenesis during embryogenesis 13. Here, we investigate its role in differentiated 
ducts after birth. In the post-natal pancreas, acinar cells do not derive from ducts 12,14,15, 
allowing analysis of the role of Hnf1b in duct function and the consequences on acinar 
cell homeostasis. 
Our data show that Hnf1b has a crucial function in the regulatory network 
controlling differentiated epithelial ductal cells and maintenance of the primary cilium. 
Its ductal function is critical to maintain acinar homeostasis as loss of Hnf1b in ductal 
cells leads to chronic pancreatitis and neoplasia. Thus, Hnf1b deficiency causes 
dysfunction of the exocrine pancreas, providing further insights into the etiology of 


















Post-natal inactivation of Hnf1b in pancreatic ducts leads to loss of primary cilia 
and cystic duct formation 
To perform a postnatal conditional inactivation of Hnf1b in ductal cells, we 
generated Sox9-CreER;Hnf1bfl/fl;R26RYFP mutants and conditionally inactivated Hnf1b 
during the first three days after birth (P1-P3), further mentioned as Hnf1b∆duct mutants. 
We analyzed the consequences on pancreata dissected 5 days after the last tamoxifen 
injection, at P8. We assessed that Hnf1b inactivation in pancreatic ductal cells was 
efficient by RT-qPCR, showing a 65% decrease in Hnf1b expression in mutants (Figure 
1A). By immunostaining, we observed nuclear Hnf1b localization in ductal structures in 
controls (Figure 1B-C), whereas Hnf1b was absent from GFP positive ducts in mutants. 
Hnf1b protein persisted in only 14% of non-recombined ducts, negative for GFP (Figure 
1D). 
As a transcription factor, Hnf1b controls a network of genes involved in duct 
morphogenesis during development 13. In order to investigate the role of Hnf1b in 
differentiated ducts after birth, we analyzed the expression of genes involved in the 
maintenance of the primary cilium and in ductal cell integrity and functionality (Figure 
1E). In Hnf1b∆duct mutants, we found by RT-qPCR a significant decrease in expression of 
cystic disease genes, known as direct targets of Hnf1b in renal cells or in pancreatic 
progenitors 13-17. We observed a strong decrease in Pkhd1, Cys1, Spp1 and Prox1 
expression, involved in ciliary maintenance and/or tubular architecture 18-21. 
Tg737/Ift88 required for ciliogenesis was also significantly downregulated. By contrast, 














controls, showing that ductal cell differentiation is maintained. Moreover, expression of 
Cftr was unaffected in Hnf1b∆duct mutants. 
As we found a specific downregulation of genes involved in the maintenance of 
the ductal primary cilium, we examined primary cilia in Hnf1b∆duct mutants. 
Immunostaining of acetylated α-tubulin (AcTub), a tubulin modification present on 
primary cilium axonemes, revealed a loss of cilia in ductal cells of Hnf1b∆duct mutants 
(Figure 1F, G). This was confirmed by the absence of Arl13b immunostaining, a cilium-
specific membrane protein (Figure 1H, I). Quantification showed a 73% decrease in 
ciliated ductal cells in Hnf1b∆duct mutants (Figure 1J), in agreement with the level of 
Hnf1b inactivation efficiency. To correlate Hnf1b inactivation and the loss of the primary 
cilium at the cellular level, we performed AcTub/GFP co-immunostainings. Hnf1b-
inactivated ducts labeled with GFP do not present any cilia (Figure 1K-M). 
As loss of cilia may promote aberrant cell division, permitting increased 
proliferation 22, we quantified proliferation of ductal cells by Sox9/Phospho-histone H3 
(PPH3) immunostainings (Figure 1N-O). Mutant ducts presented more proliferative cells 
than control pancreatic ducts (1.4-fold) (Figure 1P). This resulted in a significant 
increase of the ductal cell area (1.2-fold) quantified by the number of Sox9+ cells (Figure 
1Q). 
We investigated if these abnormalities could lead to cyst formation. By 
Hematoxylin & Eosin (H&E) staining, we observed dilated ducts in Hnf1b∆duct mutants 
(Figure 1R, S). Sox9 and Hnf6 exhibited nuclear staining of enlarged mutant ductal 
structures (Figure 1T, U and data not shown), showing that dilated ducts still express 
some terminal differentiation markers. We further analyzed ductal cell polarity. Control 
ducts showed strong apical localization of Muc1 and PKCz in epithelial cells around the 














dilated ducts (Figure 1W’) whereas it was reduced and discontinuous in the cells lining 
cysts in mutants (Figure 1W’’). Whereas the Spp1/osteopontin matricellular protein was 
localized on the apical side of control ductal cells, we observed very few Spp1+ cells in 
mutants, confirming RT-qPCR results (Figure 1Z, AA). 
Altogether, these results show that Hnf1b has a prominent role in the regulatory 
network controlling the maintenance of the primary cilium and tubular architecture of 
pancreatic ducts after birth.  
 
Post-natal inactivation of Hnf1b in pancreatic ducts leads to non-cell autonomous 
effects on acinar cells through activation of the YAP mechano-transducer 
A direct antagonistic interaction between ciliogenesis and YAP function has been 
shown 23. YAP activation was also observed in hepatic cystogenesis associated with 
Pkhd1 deficiency 24. YAP has a central role as mechano-effector and sensor of cell 
polarity, being a mediator of mechanical cues and linking the physicality of cells and 
tissues to potent transcriptional responses. It is mechanically regulated by various 
regimens of cell stretching, such as deformations of epithelial monolayers 25-27. In 
Hnf1b∆duct mutants, we visualized the deformation of pericystic areas with an 
immunostaining of the fibroblast marker α-smooth muscle actin (α-SMA) at P8. While α-
SMA+ cells were restricted around blood vessels in control pancreata (Figure 2A), 
mutants exhibited widespread α-SMA staining showing activation of fibroblasts 
surrounding ducts and in periacinar spaces (Figure 2A, B). Interestingly, we observed an 
increased number of cells with YAP nuclear staining in Hnf1b∆duct mutants in pericystic 
and acinar areas (Figure 2C-F). Consistent with YAP activation, we found a strong 














Hnf1b∆duct mutants compared to controls (Figure 2G). To determine in which cell type 
we observed the YAP nuclear enrichment, we performed co-immunostainings for 
YAP/Sox9 and YAP/Amylase to analyze ductal and acinar cells respectively. While in 
controls YAP localized only in the nucleus of Sox9+ ductal cells (Figure 2H-M), in 
mutants, it localized also ectopically in Amylase+ acinar cells (Figure 2N-S), suggesting 
that mechanical stress induced by enlarging cysts stimulates YAP activation in acinar 
cells at P8. These data show cell autonomous and non-cell autonomous upregulation of 
the YAP pathway when Hnf1b is inactivated in ductal cells.  
 
Post-natal inactivation of Hnf1b in ducts leads to acinar-to-ductal metaplasia, loss 
of acinar cells and lipomatosis 
YAP nuclear localization and increased expression of the YAP target gene Ctgf is 
particularly interesting because of its involvement in ECM fibrosis 28,29.  Accordingly, we 
observed a marked increase in periductal collagen deposition as indicated by 
histological analysis with Masson’s Trichrome at P8 (Figure 3A, B; green areas). These 
changes are reminiscent of pancreas fibrosis, which is often associated with ADM. As it 
was recently shown that YAP activity is necessary and sufficient for ADM and 
pancreatitis induction 30-32, we examined whether acinar cells were secondarily affected 
in mutants. Whereas we found no significant changes in acinar gene expression by RT-
qPCR at P8 (Figure 3C), we already observed at this stage a 41% decrease in the number 
of Amylase+ cells (Figure 3D). We found an upregulation of EGFR expression in mutants 
(1.6-fold), whereas TGFβ-1 remained unchanged at this stage (Figure 3E), both known to 
promote ADM 33-35. Moreover, Amylase/PPH3 immunostaining quantifications revealed 














a 15.5-fold increase in acinar cell apoptosis (Figure 3I-K) in mutants compared to 
controls. Hence, a combined reduction in acinar cell proliferation and an increase in 
apoptosis leads to acinar cell loss. Then, large areas of ADM were observed at P25 in 
mutants (Figure 4A, B), associated with a dramatic decrease in acinar gene expression 
(89% for amylase, Figure 4I) and a strong upregulation of Sox9 (2.2-fold, Figure 4J). 
Moreover, Sox9 and Hnf6 were ectopically expressed in some acinar cells in mutants 
(Figure 4E-H), characterizing ADM 36. As previously shown in a model of TGF-β induced 
ADM 37, we also found an ectopically induced Hnf1b expression in acinar cells at P25 
(Figure 4C, D). At this stage, ducts were more affected than at P8 as indicated by the 
complete loss of Muc1 apical staining in mutants (Figure 4K-L), which corroborated 
with the dramatic decrease in Muc1 transcript levels (Figure 4J). We found a 55% 
decrease in Hnf6 expression (Figure 4J), with few Hnf6+ cells remaining in mutants 
ducts compared with ductal Sox9+ cells (Figure 4C-F), in agreement with our finding 
that Hnf6 is a direct target of Hnf1b during pancreas development 13. By Amylase/Pan-
CK co-immunostainings, acinar structures appear closely connected with this ductal 
network and more importantly Pan-CK co-localized with some Amylase+ cells in 
mutants (Figure 4M, N). We noticed sparse area with fat infiltration only in mutants and 
identified that these fat-containing cells were adipocytes using the Fabp4 marker 
(Figure 4O-P), fatty replacement of pancreatic parenchyma being often associated with 
pancreatic fibrosis and pancreatitis 4. YAP pathway was dramatically upregulated in 
mutants, stronger than at P8: 8.6-fold for Ctgf, 6.3-fold for Lamc2 and 2.8-fold for Cyr61 
(Figure 4Q). The Notch pathway was shown to be activated during acinar 
dedifferentiation and to promote ADM 38. We found an upregulation of most of Notch 
components (Figure 4R), and especially a 2.4-fold increase in Notch2 expression, a 














Jag1 expression, which was shown to be upregulated in expanded ducts of chronic 
pancreatitis patients 40. At this stage, we also observed a strong increase (3.6-fold) in 
TGF-β1 expression in mutants and a significant increase in p8/Nupr1 expression (Figure 
4S), a transcriptional cofactor expressed at only low levels in normal pancreata but 
induced in the initial phases of pancreatitis 41. 
Hence, Hnf1b loss of function in ducts leads to loss of acinar cells and ADM, as 
well as lipomatosis in the pancreas, together with the upregulation of Yap, Notch and 
TGF-β1 pathways. 
 
Post-natal inactivation of Hnf1b in ducts leads to chronic pancreatitis in adults 
We further investigated the progression in adults of the pancreatic exocrine 
disorder associated with ductal Hnf1b-deficiency. We observed a 43% decrease in 
pancreas weight at 2 months in mutants, whereas mouse weight was unchanged 
compared to controls (Figure 5A). At 5 months, mouse weight was significantly 
decreased in mutants as a consequence of pancreatic exocrine deficiency (data not 
shown). The decreased pancreatic weight was correlated with a dramatic loss of acinar 
tissue (Figure 5B, C) correlated with a 95% decrease in acinar gene expression (Figure 
5I). Many lobes of Hnf1b∆duct mutant pancreata were entirely devoid of acinar tissue and 
merely consisted of isolated ducts embedded within a large mass of fat. Extensive ADM 
was demonstrated by very few acini scattered in the tissue and displaying enlarged 
lumen (Figure 5E), duct-like structures (Figure 6F) and a strong Sox9 ectopic 
localization in acinar cells (Figure 5G-H). Mutant pancreata displayed inflammation 
(Figure 5J). We observed a dramatic increase in F4/80 expression, a marker of 














marker of B cells was unchanged (Figure 5K). In correlation, we found an upregulation 
of CCL2, CCL5 and CXCL10, showing the involvement of these chemokines in the mutant 
inflamed pancreas. Infiltration of macrophages was also observed by F4/80 
immunostaining (Figure 5L, M), having important role in the pathogenesis of 
pancreatitis. Moreover, extensive lipomatosis was observed in mutants (Figure 5J). 
Fabp4 immunostaining showed extended areas of adipocytes (Figure 5N, O) and PPARg 
expression, a key player in adipocyte differentiation 42, was dramatically increased 
(16.6-fold) in mutants (Figure 6P). The pancreatic parenchyma of the mutant was 
replaced by fibrotic tissue as shown by Masson’s Trichrome (Figure 5Q, R) and a 10.2-
fold increase in the expression of the desmoplasia-associated marker Col1A1 in mutants 
(Figure 5S). We observed a 12.8-fold increase in α-SMA expression in mutants, showing 
pancreatic stellate cell (PSC) activation, a key mediator in the fibrosis observed in the 
desmoplastic reaction 43 (Figure 5V). Interestingly, we found a strong accumulation of 
the mesenchymal-related protein Vimentin in mutants (Figure 5T, U) correlated with a 
dramatic increase in Vimentin expression (47.7-fold) (Figure 5V), as well as up-
regulation of another mesenchymal marker N-cadherin (5.5-fold). Inversely, the 
epithelial marker E-cadherin was dramatically downregulated (87%), showing 
epithelial-mesenchymal transition (EMT). 
Thus, inflammation, fibrosis, activation of PSCs and EMT promote chronic 
pancreatitis in adult Hnf1b∆duct mutants. 
 
Post-natal inactivation of Hnf1b in ducts leads to pancreatic neoplasia and 















Chronic pancreatitis has been shown to predispose to pancreatic cancer 1. 
Activated signaling pathways play a role in ADM and also in early PanIN lesions. We 
therefore investigated potential development of PanINs in adult Hnf1b∆duct mutants. 
CTGF production is abundant in the desmoplastic stroma present in pancreatic 
cancer 44. We found a 4.4-fold increase of Ctgf expression in adult Hnf1b∆duct mutants  
(Figure 6A), and strong ectopic CTGF protein localization in acinar cells in mutants 
compared to controls (Figure 6B, C). Moreover, we observed strong CTGF expression in 
the epithelium of metaplastic ducts (Figure 6D) and in neoplastic lesions (Figure 6E) in 
Hnf1b∆duct mutants. Cyr61 was recently reported to be expressed in PanINs, Cyr61 
signaling being critical for EMT and promoting pancreatic carcinogenesis 45. We found a 
dramatic increase (6.1-fold) of Cyr61 in adult Hnf1b∆duct mutants, as well as Lamc2 and 
Birc5, other markers of the YAP pathway (Figure 6A).  
TGF−β pathway activation plays a crucial role in pancreatic tumor initiation 
through its capacity to induce ADM, providing a favorable environment for neoplasia 37. 
We found a 12.8-fold increase in TGF-β1 expression in mutants compared to controls 
(Figure 6F), with a 4-fold increase compared to mutants at P25. Moreover, Phospho-
Smad2 protein was strongly ectopically localized in the nuclei of ADM structures, 
metaplastic ducts and fibrotic tissue (Figure 6G, H), monitoring the activation of the 
TGF-β signaling pathway in adult Hnf1b∆duct mutants. 
Ectopic Notch activation, promoting both initiation and progression of PanINs, is 
also an early event in pancreatic carcinogenesis 46. We found a strong up-regulation of 
Notch pathway components, higher than at P25 especially for the receptor Notch2 and 
the effector Hey2, (6.4-fold and 5.9-fold respectively, Figure 6I). In correlation, Hey2 
protein was observed ectopically in acinar cells, in enlarged ducts and in ADM structures 














pancreatic tumorigenesis 34 and we observed a strong up-regulation of EGFR (2.3-fold; 
Figure 6L) in adult Hnf1b∆duct mutants, along with a strong localization of Phospho-AKT 
in the fibrotic and inflamed tissue of the mutant pancreas (Figure 6M, N).  
Remarkably, histological analysis showed intraepithelial neoplasia as low-grade 
PanINs in Hnf1b∆duct mutant pancreata (Figure 7A). These were characterized by an 
epithelium composed of tall columnar cells with basally located nuclei with light atypia, 
a pseudostratified architecture and abundant supranuclear mucin. These neoplastic 
structures were Alcian Blue-positive (Figure 7B) and positive for the PanIN-specific 
marker Claudin18 (Figure 7C). Thus, loss of Hnf1b leads to pancreatic neoplasia by 2 
months. By GFP immunostainings, we performed a lineage tracing analysis and found no 
GFP signal in ADM/PanIN in Hnf1b mutants strongly suggesting that PanIN like 
structures derived indirectly from Hnf1b-ablated YFP+ ductal cells, by a non-cell 
autonomous mechanism (Figure 7 D).  
By quantification of the acinar compartment in mutants, 11.6% of remaining acini, 
80.8% of adipocytes, 6.1% of fibrosis/infiltrates, 1.3% of ADM and 0.5% of PanIN were 
observed in mutants (Figure 7E). By analyzing older animals until 18 months, we did not 
observe PanIN progression (data not shown). We then investigated if loss of Hnf1b 
could promote tumorigenesis in a context of oncogenic Kras (KrasG12V). Somatic 
activating mutations in Kras indeed appear in 97% of PDAC patients, but additional 
factors are required to initiate PanIN progression and PDAC. To activate Kras in acinar 
cells, we used the Elas-tTA; TetO-Flpase; FRT-Stop-FRT KrasG12V mouse line. Untreated 
mice (without doxycycline) develop PanIN lesions with long latency, with low grade 
PanIN from 5/6 months. We crossed these mice, hereafter referred to as Kras, with 
Sox9-CreER;Hnf1bfl/fl Mutants to obtain Elas-tTA; TetO-Flpase; FRT-Stop-FRT KrasG12V/ 














Mutants. Histological analyses by HE staining (Figure 8A), Alcian Blue staining (Figure 
8B), and Claudin 18 immunohistochemistry (Figure 8C) at 5 months showed large area 
of PanINs in Kras;Mutants compared to mutants and age-matched Kras, affecting more 
lobules with very large amount of lesions. This showed that combination of Hnf1b 
deletion with oncogenic KRAS activation enhanced pancreatic damage at 5 months 
relative to oncogenic KRAS alone. Quantification of Alcian Blue positive lesions showed a 
dramatic increase in the surface of lesions in Mutant;Kras compared to mutants and 
Kras (Figure 8D), which was due to a combined increase in the number of lesions 
(Figure 8E) and in the size of the lesions (Figure 8F) in Mutant;Kras. Moreover, we 
observed an increased progression of PanIN lesions up to high grade at 5 months in 
Mutant;Kras (Figure 8G-K).  Thus, Hnf1b inactivation in ducts provides a propitious 
environment for the onset of KRASG12D-induced PanINs. 
 
Adult inactivation of Hnf1b in ducts leads to impaired acinar regeneration following 
caerulein-induced pancreatitis 
 We next tested the hypothesis that Hnf1b could be required for maintenance of 
exocrine homeostasis in the adult. We inactivated Hnf1b in adult ductal cells, with TM 
injections on 6-weeks old mice and observed the consequences on the pancreatic tissue 
at 9 weeks and 20 weeks. We did not observed changes in pancreatic weight in these 
mutants compared to controls (Figure 9A,C). Analysis of acinar marker expression by 
RT-qPCR (Figure 9B, D) and H&E stainings (Figure 9E,F) yielded no overt pancreatic 
pathology at either time point when Hnf1b was inactivated in adult ducts, probably due 
to the lower proliferation rate of adult ductal cells compared to post-natal ductal cells 5. 
Thus, we investigated if loss of Hnf1b in adults would sensitize acinar cells to injury-














regeneration 47,48. Two weeks post-TM in adults, acute pancreatitis was induced by 2 
consecutive days of treatment with the secretagogue cerulein, and pancreata were 
harvested 1 week later (D7). We verified that Hnf1b inactivation was also efficient at this 
stage, and observed a 50% decrease in Hnf1b expression in Hnf1b∆adult duct mutants 
(Figure 10A). We followed Amylase expression by RTq-PCR and found no significant 
changes between controls and mutants at D0 and D3. Amylase expression was 
dramatically decreased at D3, showing the efficiency of the cerulein treatment (Figure 
10B). Whereas controls showed a recovery of Amylase expression at D7, Hnf1b∆adult duct 
mutants were unable to recover after injury, showing dramatically low levels of Amylase 
expression in mutants (99% decrease). Other acinar markers displayed the same 
pattern of expression with critically low levels of CPA, Ptf1a, Mist1 and Nr5a2 expression 
in Hnf1b∆adult duct mutants compared to controls at D7 (Figure 10C). In mutants, we 
observed a dramatic increase in F4/80 and CD2 expression, whereas expression of the B 
cell marker CD19 was unchanged (Figure 10D), showing a increased severity of 
pancreatitis in mutants with macrophages and T cells recruitment. We found a tendency 
but not a significant increase in the mRNA level of CCL2, CCL5 and CXCL10 chemokines 
in mutants at D7, suggesting that the chronic pancreatitis was more established in Hnf1b 
mutant at 5 months after perinatal inactivation (Figure 5K), than in adult Hnf1b mutants 
7 days after cerulein treatment (Figure 10D). Histological analysis by H&E and Masson’s 
Trichrome showed no abnormalities at D0, but ADM and interstitial fibrosis at D3 both 
in controls and mutants. At D7, whereas control pancreata were recovered, we observed 
persistent and strong defects in Hnf1b∆adult duct mutant pancreata, characteristic of 
chronic pancreatitis (Figure 10E). No large Amylase+ acinar clusters were detected in 
Hnf1b∆adult duct mutant pancreata in contrast to controls, and co-localisation of Sox9 and 














(Figure 10F, G), showing widespread ADM at D7. Remarkably, we observed abundant 
persistent metaplastic lesions, fibrosis, and formation of neoplastic lesions, as shown by 
histology on H&E (Figure 10H, I), alcian-blue stainings (Figure 10J, K), and by 
immunohistochemistry with the PanIN-specific marker Claudin18 (Figure 10L, M). 
These results show the requirement of Hnf1b in adult ducts for acinar cell regeneration 
in the context of tissue injury. Our data further suggest that Hnf1b deficiency in adult 




We show that Hnf1b inactivation in ductal cells after birth causes loss of primary 
cilia, duct proliferation and dilatation. This triggers fibrosis, ADM, inflammatory 
infiltration, lipomatosis, activation of PSC and EMT, leading to chronic pancreatitis and 
PanINs. 
 
Hnf1b-inactivation in differentiated post-natal pancreatic ducts leads to 
chronic pancreatitis  
Ductal Hnf1b inactivation leads to dramatic decrease in cystic-disease associated 
gene expression, especially Pkhd1 and Cys1, reinforcing our previous findings that they 
were direct targets of Hnf1b in pancreatic progenitors at E12.5 13. Pkhd1, Cys1, and 
Tg737/Ift88 play a role in the structural integrity of cilia. The Pkhd1 gene encodes 
Fibrocystin, a membrane protein localised to the primary cilium of tubular epithelial 
cells 49 and lack of Fibrocystin disrupted ciliogenesis in Pkhd1-deficient mice 50. 














chronic pancreatitis 51. The Cys1 gene product, Cystin, also localizes to the primary 
cilium and stabilizes microtubule assembly 52. The protein IFT88/polaris is a core 
component of the intraflagellar transport machinery and is required for the formation of 
cilia 53. Primary cilia transduce signals from extracellular stimuli to a cellular response 
that regulates proliferation, differentiation, transcription, migration, polarity and tissue 
morphology 54. They can play a negative role in epithelial cell proliferation 55. Mutations 
affecting cilia development promote a dilated ductal phenotype or cyst formation 8, 9, 56. 
In correlation with the loss of primary cilia, we found increased proliferation of ductal 
cells in Hnf1b∆duct mutant pancreata. Moreover, this leads to duct dilatation and partial 
loss of apico-basal polarity of epithelial ductal cells. Some Hnf1b∆duct mutant ducts were 
devoid of primary cilia, whereas they were not dilated, strongly suggesting that duct 
dilatation occurs secondary to the loss of primary cilia. Furthermore, Muc1 
immunostaining was still observed in some dilated ducts. We observed weaker 
expression of Muc1 at P25 whereas it was unchanged at P8. This strongly suggests that 
loss of apico-basal polarity is a consequence of duct dilatation. Pkhd1 is also involved in 
the tubulogenesis and/or maintenance of duct–lumen architecture 49 and its decreased 
expression likely contributes to duct dilatation in Hnf1b∆duct mutants. Prox1 was 
significantly downregulated in Hnf1b∆duct mutants by P8 and it was previously shown 
that Prox1 inactivation results in dilated pancreatic ducts and ADM. Prox1 mutant adult 
pancreata uncovered features of chronic tissue damage: acinar apoptosis, macrophage 
infiltration, mild fibrosis, and extensive lipomatosis 21, suggesting that reduced Prox1 
expression contributes to the phenotype observed in Hnf1b∆duct mutants. Lineage 
tracing analysis showed that adipocytes of Prox1 mutant pancreata did not originate 
from trans-differentiated pancreatic acinar cells 21, suggesting that this may also be the 














were also reported in pancreata devoid of Hnf6 56,57. Pancreatitis was observed in Hnf6 
mutant animals 57, associated with the finding of shorter primary cilia of ductal cells 58. 
We observed a decreased expression of Hnf6 at P25 whereas it was unchanged at P8, 
showing that loss of Hnf6 can contribute secondarily to the phenotype. Our data further 
underscore the link between primary cilia and pancreatitis. Defects in cilia have been 
associated with a spectrum of human diseases collectively called ciliopathies 59. Ductal 
cysts, polarization defects, dysplasia and fibrosis of the pancreas have been described in 
many ciliopathies. The absence of pancreatic cilia during mouse embryogenesis in Kif3a 
mutants or in hypomorphic Tg737 mutants (Tg737orpk) resulted in lesions that resemble 
those found in patients with pancreatitis or cystic fibrosis 7–9. However, the function of 
ducts and primary cilia in post-natal pancreatic tissue homeostasis was largely unknown. 
We show here that Hnf1b inactivation leads to loss of primary cilia and duct dilatation, 
Hnf1b being necessary for the expression of Pkhd1, Cys1 and Prox1 in pancreatic ducts. 
Our results are also of particular interest since genes we found downregulated in 
Hnf1b∆duct mutant pancreata are also linked to pancreatic neoplasia 60–62. 
 
Hnf1b-inactivation in pancreatic ducts leads to neoplasia and enhances the 
ability of oncogenic KRAS to promote precancerous lesions.  
As cilia have the ability to physically influence the cell cycle and fine-tune 
signaling cascades, loss of primary cilia may promote tumorigenesis through aberrant 
signal transduction. Ciliogenesis was indeed found suppressed in tumor cells, including 
PanINs and PDAC 63. YAP was shown to promote cell proliferation 64 and we observed an 
upregulation of the YAP pathway and an increased proliferation of ductal cells in 
Hnf1b∆duct mutants. Recent studies have highlighted the role of YAP in the regulation of 














activation was associated with hepatic cyst epithelium proliferation in autosomal 
recessive polycystic kidney disease (ARPKD) 24. Moreover, YAP functions as a mechano-
responsive transcriptional co-activator 25-27. Our data suggest that mechanical stress 
induced by enlarging cysts stimulates YAP activation in pericystic and acinar cells. As 
YAP activity is necessary and sufficient for ADM and pancreatitis induction 30-32, YAP 
constitutes a molecular link between Hnf1b deletion in ductal cells and the non-cell 
autonomous effects on acinar cells. Moreover, YAP drives fibrosis by activating 
fibroblasts 29. YAP transcriptional targets were progressively overexpressed from P8 to 
the adult stage: CTGF and Lamc2 from P8, Cyr61 by P25 and Birc5 in adults. All of them 
were strongly upregulated in adults, 4- to 10-fold. In correlation, a 4.5-fold increase in 
CTGF expression was observed in human chronic pancreatitis 65. CTGF is involved in cell 
adhesion, cell migration, inflammation, pancreatic fibrosis, tumor growth and metastasis, 
and it is overexpressed in human pancreatic cancer 66. Thus, fibrosis is likely caused by 
increased CTGF expression and this fibrotic microenvironment promotes PanINs in 
Hnf1b∆duct mutant pancreata. Moreover, LAMC2 was recently identified as a new 
putative pancreatic cancer biomarker 67. EGFR, promoting ADM and PanINs 34, is also 
involved in ADM induction and formation of neoplastic lesions in Hnf1b∆duct mutants, as 
upregulation of EGFR in mutants was observed from P8, with a 2-fold increase in adults. 
From P25, Notch and TGF-β signaling contribute to ADM, fibrosis, activation of PSCs and 
PanINs development in Hnf1b∆duct mutants, with a 2-fold upregulation at P25 and 6-fold 
in adults for Notch signaling, a 4-fold upregulation at P25 and 13-fold in adults for TGF-
β1 in Hnf1b∆duct mutants. The selective dramatic up-regulations of Notch2 and Hey2 in 
Hnf1b∆duct mutants are in accordance with the finding that centroacinar and terminal 
ductal epithelial cells did not display up-regulation of Hes1 transcripts, but did exhibit 














Notch2 is expressed in ductal cells and PanIN lesions and is a central regulator of PanIN 
progression and malignant transformation 69. Notch indeed regulates ADM and 
promotes both initiation and progression of PanINs 2,38,46. As TGF-β was shown to 
trigger ADM in acinar cells 37, it would be interesting to further test the requirement of 
TGF-β activation to drive ADM in Hnf1b∆duct mutants with the use of TGF-β inhibitors. 
TGF-β signaling is also pivotal in driving fibrogenesis, for activation of PSC and for PanIN 
formation 44,70. Thus, activation of the YAP pathway, EGFR pathway, and subsequent 
upregulation of the Notch and TGF-β pathways support the non-cell autonomous effects 
leading to ADM, PSCs activation, fibrosis and PanINs in Hnf1b∆duct mutants.  
Furthermore, we observed an increase in both the number and the grade of PanIN 
lesions in the pancreas of mice combining both perinatal Hnf1b inactivation in ducts and 
oncogenic Kras activation in mature acinar cells, showing that loss of Hnf1b promotes 
PanIN formation in a Kras activated context. Thus, the environnement due to Hnf1b 
inactivation is favorable for KrasG12V-dependent carcinogenesis.  
Increased risk for neoplastic conversion have also been linked to perturbations in 
pathways that control tissue regeneration 71. We examined the role of Hnf1b in adult 
ducts in the process of tissue injury and regeneration, in the cerulein-induced acute 
pancreatitis model 72. Remarkably, our findings show that Hnf1b inactivation in adult 
ductal cells is associated with impaired acinar regeneration and chronic inflammation, 
allowing ADM and PanIN formation in the context of tissue injury in adults. Whether this 
role is due to Hnf1b function in terminal ducts or centroacinar cells will require further 
investigations. 
 
HNF1B role in etiology and physiopathology of the human diseases 















HNF1B heretozygous mutations are notably associated with MODY5 diabetes, 
pancreas exocrine dysfunction (pancreatitis with reduced fecal elastase concentration in 
93% of these cases, fecal fat excretion) and pancreas structural anomalies (atrophy, 
cysts, calcification) 73. Pancreatitis was surprising to observe as Hnf1b is not expressed 
in acinar cells and it was proposed that this defect might be caused by pancreas 
hypoplasia. The results of the present study show that pancreatitis associated with 
Hnf1b deficiency is caused by pancreatic duct alteration. Moreover, differences observed 
from one patient to another might be due to impaired recovery of the pancreas in adults 
as our results also show that Hnf1b deficiency leads to altered acinar regeneration 
following injury. 
Studies have shown that downregulation of HNF1B is associated with cancer risk, 
including renal, prostate, ovarian and colorectal cancers, showing that HNF1B is a 
marker of these cancers and a potential tumor suppressor 74–78. Pancreatic cancer is 
poorly characterized at genetic and non-genetic levels. Recent analyses suggested that 
reduced HNF1B activity could also be an important step in pancreatic tumorigenesis. 
Mutations in HNF1B have been identified as markers of pancreatic cancer risk loci 
through GWAS analyses 79-81. In PDAC tissues and pancreatic cancer cell lines, HNF1B 
was down-regulated compared to normal pancreatic tissues and this loss of expression 
contributed to disease aggressiveness 62,80. Recently, a regulatory network analysis 
reported that HNF1B, among thousand transcription factors, was the top enriched gene 
expressed in the normal pancreatic tissue compared to the PDAC regulatory network, 
identifying HNF1B as a master regulator of PDAC and its subtypes 82. The present study 
is the first to demonstrate that loss of Hnf1b activity can induce pancreatitis, pancreatic 














molecular mechanisms that link Hnf1b dysfunction to pancreatic neoplasia and 
tumorigenesis. Understanding the first steps of pancreatic tumorigenesis is important 
and may provide new therapeutic strategies aimed at restoring a normal differentiated 
state. Hnf1b appears to act as a pancreatic tumor suppressor, important for the 
epithelial state maintenance. Hnf6, one downstream target of Hnf1b, was also proposed 
as a tumor suppressor 61, suggesting that maintenance of the ductal phenotype could be 
important in cancer prevention. Defining the molecular mechanisms underlying the 
initiation of pancreatic cancer is highly relevant for the development of early detection 
markers and of potentially novel treatments. Insight on the role of Hnf1b in pancreatic 
cancer development could lead to its use as a biomarker for early detection and 
prognosis. Reinforcing HNF1B expression may represent a novel therapeutic strategy to 
improve the survival of patients with PDAC, together with restoring ciliogenesis by 
pharmacologic means in order to improve the effectiveness of other curative options. 
Thus, these new insights offer potential novel therapeutic strategies. 
 
 
Material and Methods 
 
Mouse lines 
The Hnf1b conditional knockout (Hnf1btm1Ics denoted as Hnf1bflox/flox) carrying LoxP sites 
flanking exon 4 13 and Sox9-CreERT2 14 lines have been previously described. The 
R26RYFP line (B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J) from the Jackson Laboratory 
was used to assess recombination efficiency. We performed a conditional deletion of 
Hnf1b in pancreatic ducts by crossing the Hnf1b-floxed mouse line with the tamoxifen 














mutants. Hnf1bfl/+ or Hnf1bfl/fl mice are referred to as controls. Heterozygous Sox9-
CreER;Hnf1b+/fl mice showed no phenotype (data not shown). The Elas-tTA; TetO-
Flpase; FRT-Stop-FRT KrasG12V line expressed FLP recombinase under the control of the 
elastase promoter in a tet-off system, allowing selective expression of the KrasG12V 
oncoprotein in pancreatic acinar cells. Untreated mice developed PanIN lesions with a 
long latency 83 and were used in crossings with Sox9-CreER;Hnf1bfl/fl mutants with TM 
induction perinataly to assess if ductal Hnf1b inactivation promotes PanIN progression 
in concert with Kras activated in acinar cells. Elas-tTA; TetO-Flpase; KrasG12V are 
referred to as Kras and Sox9-CreER;Hnf1bfl/fl;Elas-tTA; TetO-Flpase; KrasG12V are referred 
to as Mutant;Kras. Animal experiments were conducted in accordance with French and 
European ethical legal guidelines and the local ethical committee for animal care 




Tamoxifen (Sigma-T5648) was dissolved at 25 mg/ml in corn oil and administrated 
intraperitoneally to mice at a dose of 7mg/40g of mouse. For postnatal inactivation, 
tamoxifen injections were performed on lactating females during 3 consecutive days 
following birth, with 1 injection per day (P1, P2, P3), allowing pups to receive tamoxifen 
through breast milk. Dissections were done at P8, P25, 2-months and 5-months. For 
adult inactivation, Tamoxifen was injected during 4 consecutive days, with 1 injection 
















2 weeks after adult Hnf1b inactivation with TM injections of 10-weeks old mice, mice 
were injected with cerulein (Sigma-C9026), a decapeptide analogue of the pancreatic 
secretagogue cholecystokinin that induces acinar cell death, at a dose corresponding to 
75 µg/kg. Cerulein was dissolved at 1 mg/ml in NaCl and administrated to mice at 5 µl/g 
by injections intraperitoneally hourly, 7 times a day, for 2 consecutive days. Pancreata 
were harvested at 3 different times after the first cerulein injection: just before cerulein 
injection at day 0 (DO), when acute pancreatitis was induced at day 3 (D3), and when 
the pancreas was almost fully regenerated at day 7 (D7). 
 
Histology, Immunohistochemistry and Immunofluorescence 
Dissected pancreata were fixed in 4% formaldehyde overnight and embedded in 
paraffin. Sections (7 µm thick) were prepared, deparaffinised and rehydrated for 
histological stainings. For Hematoxylin & Eosin (H&E) staining, slides were incubated 
with Harris solution (Sigma- HHS16) for 1 min and in Eosin (Sigma-HT110216) for 3 
min. For Masson’s Trichrome staining, slides were incubated with Harris for 5 min, 
rinsed with lithium carbonate and water, then incubated with Funchsin-Ponceau for 3 
min and rinsed with acidified water and 1% phosphomolibdic acid. Slides were then 
stained with 1% light green for 20 min and rinsed with acidified water. For Alcian Blue 
staining, slides were incubated with Alcian Blue solution (pH2.5) for 30 min, prepared 
with Alcian Blue 8GX (Sigma-A3157) in 3% acetic acid, rinsed with water and 
counterstained with Nuclear Fast Red solution for 5 min. Slides were dehydrated before 
mounting.  
Sections were processed for immunofluorescence or immunohistochemistry using a 
previously described protocol 16. Briefly, epitope retrieval was performed by heating the 














performed in PBS/TritonX-100 0.3%, and sections were incubated in blocking solution 
(10% milk, 1% BSA 0.1% 10X Triton-X in PBS 1X or 1.5% Horse/Goat Serum in PBS 1X) 
before antibody staining. Nuclei were stained with DAPI (1/1000-Sigma) in the 
secondary antibody staining step. For signal amplification, we used a biotinylated anti-
rabbit or anti-goat antibody before incubating with Steptavidin-Alexa594 or 
Steptavidin-Alexa488. Epitope retrieval for CTGF immunohistochemistry was 
performed by heating slides in a pressure cooker for 15 minutes. Slides were then 
incubated in 3% H2O2 before blocking to eliminate endogenous peroxidase activity. For 
all other immunohistochemistry experiments, slides were incubated in 1% H2O2/50% 
methanol solution before blocking to eliminate endogenous peroxidase activity. The 
VECTASTAIN peroxidase ABC system (Vector) was used for Sox9, F4/80, vimentin, CTGF, 
Hey2, P-AKT, P-SMAD2 and Claudin18 immunostainings. Nuclei were counterstained 
with Hematoxylin. Primary antibodies are listed in Table 1. Images were acquired using 
Zeiss Axio Observer.Z1 microscope with apotome. For histology, immunofluorescence 
and immunohistochemistry, at least 2 sections per pancreas and at least 3 different 
pancreases of each genotype were analyzed.  
 
Quantification of recombined GFP+ ducts, ciliated ductal cells, duct area, proliferation & 
apoptosis, and PanINs 
Quantification of GFP+ ducts in mutants was performed with GFP/Hnf1b 
immunostainings. More than 2500 GFP+ cells and 500 Hnf1b+ cells were counted (n=3).  
Quantification of ciliated ductal cells at P8 was performed by counting Sox9+ cells with 
the cilium stained with Acetylated Tubulin. Almost 500 cells were counted for controls 
and more than 1,000 cells for mutants (Control, n=7; Mutant, n=11). Quantifications of 














(Control, n=4; Mutant, n=4). More than 15,000 Sox9+ and 22,000 Amylase+ cells were 
counted for each genotype. The numbers of Sox9+ and Amylase+ cells per mm2 were 
obtained by dividing the numbers of Sox9+ and Amylase+ cells by the corresponding 
cross-sectional areas. 
Proliferation of ductal and acinar cells was determined by immunolabeling with 
Phospho-histone H3 (PPH3) and Sox9 or Amylase antibodies respectively. Positive cells 
were scored from at least 3 non-overlapping fields for each section at 10X magnification. 
The percentages of PPH3 positive cells were calculated by dividing the number of ductal 
or acinar cells labeled with PPH3 by the total number of cells expressing Sox9 or 
Amylase. Quantification was performed with at least 2 sections per pancreas (Control, 
n=4; Mutant, n=4). 
Acinar cell apoptosis was determined with a Terminal deoxynucleotidyltransferase-
mediated dUTP-biotin nick end labeling (TUNEL) analysis, performed using an in situ 
cell death detection kit (Roche Diagnostics) and followed by amylase immunostaining. 
Apoptosis was quantified by counting the number of labelled nuclei. The percentage of 
TUNEL-positive cells was calculated by dividing the number of TUNEL+/Amylase+ cells 
by the total number of Amylase+ acinar cells. Quantification was performed with 3 
sections per pancreas (Control, n=4; Mutant, n=4). More than 100 TUNEL stained acinar 
cells were counted in controls and more than 800 in mutants.  
All countings were performed with Adobe Photoshop CS4. 
Quantification of the % of remaining acini, adipocytes, fibrosis/infiltrates, ADM and 
PanIN was performed on histological sections of mutant pancreata (n=6) with Image 
J/Fiji software.   
Quantification of the lesion surface in Mutant;Kras compared to Kras and Mutants was 














the total surface of the pancreatic area in µm2. The results are given in percentage. Each 
image of the most representative section per sample was acquired by a macro-apotome 
Zeiss Axiozoomer and the surfaces were quantified by the Zen software. The total 
number of lesions was counted on each image acquired by the macro-apotome for each 
sample and was reported to the total surface of the pancreatic area. The results are 
given as the number of lesion per cm2. The size of each lesion was also quantified in µm2. 
Mutants n=5, Kras n=4, Mutant;Kras n= 3.  
Values are shown as mean+s.e.m. 
 
RNA extraction, Reverse-Transcription and quantitative PCR (RT-qPCR) 
Total RNA from adult pancreas was isolated using the RNeasy Mini-kit (Qiagen) and 
reverse transcribed using the Superscript RT II Kit with random hexamers (Invitrogen). 
qPCR was performed using a SYBR Green master mix (Eurobiogreen QPCR Mix, Hi-ROX, 
Eurobio). Primer sequences are provided in Table 2. The method of relative 
quantification was used to calculate expression levels, normalized to cyclophilin A and 
relative to wild-type cDNA from E15.5 pancreata. Values are shown as mean+s.e.m. 
 
 
Statistical analysis  
Statistical significance was determined using Student’s t-test or the non-parametric 
Mann-Whitney’s U test when appropriate. Statistical analyses were carried out with 
GraphPad Prism 6.0 (GraphPad Software, Inc, La Jolla, CA, USA). Differences were 
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Figure 1. Ductal deletion of Hnf1b leads to loss of primary cilia, increased ductal 
cell proliferation, dilatation, and alteration of ductal cell polarity at P8. (A) 
Analysis of Hnf1b inactivation efficiency by qRT-PCR. (B, C) Hnf1b (red) and GFP (green) 
immunostaining. Hnf1b+ ductal cells are observed in controls and recombination is 
monitored by GFP+ cells in Sox9-CreER;Hnf1bfl/fl;R26RYFP/+ mutant pancreata. (D) 
Quantification of GFP+ recombined ductal cells in Sox9-CreER;Hnf1bfl/fl;R26RYFP/+ mutant 
pancreata. (E) qRT-PCR of ductal and cystic-disease genes. (F, G) Sox9 (green) and 
acetylated α-Tubulin (Ac-Tub, red) immunostaining. (H, I) Muc1 (green) and Arl13b 
(red) immunostaining. Mutant ductal epithelial cells stained with Sox9 and Muc1 are 
devoid of primary cilia, stained for Ac-Tub (G’) and Arl13b (I’). (J) Quantification of 
ciliated ductal cells. (K, L, M) GFP and Ac-Tub immunostaining showing primary cilia 
loss in recombinant ductal cells from dilated (M’) and non-dilated (L’) ducts. (N, O) 
Phospho-histone H3 (PHH3, red) and Sox9 (green) immunostaining. (P, Q) 
Quantification of ductal Sox9+ cell proliferation and quantification of the number Sox9+ 
cells per area. Arrows indicate mitotic Sox9+ cells. (R, S) H&E staining. (T, U) Sox9 
(brown) immunohistochemistry. (V, W) PKCz (green) and β-Cat (red) immunostaining. 
(W) Asterisk shows dilated duct with loss of PKCz apical staining. PKCz apical staining is 
maintained in non-dilated duct (W’) but lost in dilated ducts (W’’). (X, Y) Mucin1 (Muc1, 
green) and β-catenin (β-Cat, red) immunostaining. (Y, Y’) Arrows show disruption of 
Muc1 staining in parts of mutant dilated ducts. (Z-AA) Spp1 (red) and Amylase (green) 
immunostaining. Loss of the apical ductal marker Spp1 is observed in mutants (AA’). 














K-M, V-W, Z-AA) 10 μm. Control, n=7; Mutant, n=7 for RT-qPCR and Control, n≥3; Mutant, 
n≥3 for immunostainings. *P<0.05; **P<0.01; ***P<0.001. 
 
Figure 2. Ductal deletion of Hnf1b leads to upregulation of the YAP pathway at P8. 
(A, B) Sox9 (green) and α-smooth muscle actin (SMA, red) immunostaining. SMA 
staining is observed in smooth muscle cells in vessel walls in controls (A), whereas SMA 
is ectopically activated in periductal cells in mutants (B). (C, D) YAP (red) and Sox9 
(green) immunostaining. (E, F) YAP (red) and Amylase (green) immunostaining. Nuclear 
YAP immunostaining is ectopically localized in periductal and acinar cells in mutants (D, 
F). (G) RT-qPCR analysis of YAP transcriptional targets. (H-M) YAP (red) and Sox9 
(green) immunostaining. Merged images show YAP/Sox9 colocalisation in ductal cells in 
controls (J’) and mutants (M’). (N-S) YAP (red) and Amylase (green) immunostaining. No 
YAP/Amylase colocalisation is present in controls (P’), whereas Amylase+ cells show 
YAP+ nuclear staining in mutants (S’). Nuclei are stained with DAPI (blue). Scale bars: 
(A-F) 50μm; (H-S) 20 μm. **P<0.01. Control, n=7; Mutant, n=7 for RT-qPCR and Control, 
n≥3; Mutant, n≥3 for immunostainings. 
 
Figure 3. Ductal deletion of Hnf1b induces pancreatic fibrosis and loss of acinar 
cells by P8. (A, B) Masson's Trichrome staining show collagen deposition in green in 
mutants. (C) qRT-PCR analysis of acinar markers. (D) Number of Amylase+ cells per area. 
(E) qRT-PCR of EGFR and TGF-β1. (F, G) Phospho-histone H3 (PHH3, red) and Amylase 
(green) immunostaining. Arrows indicate mitotic Amylase+ cells. (H) Quantification of 
acinar cell proliferation (Amylase+ PHH3+/Amylase+ cells). (I, J) TUNEL assay (green) 
and Amylase (red) immunostaining. Arrows indicate apoptotic Amylase+ cells. Nuclei are 














Control, n=4; Mutant, n=4 for quantification of immunostainings, and Control, n=7; 
Mutant, n=7 for RT-qPCR. **P<0.01; ***P<0.001.  
 
Figure 4. Ductal deletion of Hnf1b leads to ADM and lipomatosis at P25. (A, B) H&E 
staining. Arrows show acini with increased lumen size in mutants, feature of ADM. (C, D) 
Amylase (green) and Hnf1b (red) immunostaining. (E, F) Amylase (green) and Sox9 
(red) immunostaining. (G-H) Amylase (green) and Hnf6 (red) immunostaining. Arrows 
show Amylase+ cells with nuclear Hnf6+ staining, characteristic of ADM in mutants. (I) 
RTq-PCR of acinar markers. (J) RTq-PCR of Hnf6, Muc1, Sox9. (K, L) Muc1 (green) and β-
Cat (red) immunostaining. Muc1 staining is lost at the apical surface of ductal cells in 
mutants. (M, N) Amylase (green) and PanCK (red) immunostaining. PanCK localisation is 
expanded in acinar cells of mutants (N’). (O, P) FABP4 immunostaining shows 
adipocytes in mutants. (Q) RT-qPCR of YAP transcriptional targets (R) RT-qPCR of Notch 
signaling components. (S) RT-qPCR of TGF-β1 and P8/NuPr1. Scale bars: 50 μm. Nuclei 
are stained with DAPI (blue). Control, n≥3; Mutant, n≥3 for immunostainings and 
Control, n=7; Mutant, n=8 for RT-qPCR. *P<0.05; **P<0.01; ***P<0.001.  
 
Figure 5. Ductal deletion of Hnf1b leads to chronic pancreatitis at 2 months. (A) 
Pancreas weight and relative pancreas weight/body weight of 2-months old mice 
(Control, n=17; Mutant, n=11). (B-F) H&E staining. Mutant pancreata display dramatic 
loss of acinar tissue (C) and ADM (E, F). (G, H) Amylase (green) and Sox9 (red) 
immunostaining. Nuclear Sox9+ staining in Amylase+ cells is characteristic of ADM in 
mutants (H’). (I) RTq-PCR of acinar markers. (J) H&E staining shows lymphocyte 
infiltration and lipomatosis in mutants. (K) RT-qPCR of immune infiltrates (F4/80, CD2, 














marker F4/80 (brown) immunostaining. (N, O) Adipocyte marker Fabp4 (green) 
immunostaining and (P) qRT-PCR of PPARγ. (Q, R) Masson’s Trichrome staining. (S) RT-
qPCR of Col1A1. (T, U) Vimentin (brown) immunostaining. (V) RT-qPCR of SMA, 
Vimentin (Vim), N-Cad and E-Cad. Scale bars: (B, C) 2 mm; (D-H, J, L-M, Q-U) 50 μm;  (N, 
O) 100 μm. Nuclei are stained with DAPI (blue). Control, n≥3; Mutant, n≥3 for 
immunostainings and Control, n=8; Mutant, n=5 for RT-qPCR. **P<0.01; ***P<0.001.  
 
Figure 6. Ductal deletion of Hnf1b leads to enhanced signaling pathways that favor 
tumorigenesis. (A) RT-qPCR of YAP transcriptional targets. (B-E) CTGF (brown) 
immunohistochemistry. A strong ectopic CTGF staining is observed in acinar cells in 
mutants (C’) in the epithelium of metaplastic ducts (D’) and in PanIN (E’). (F) RT-qPCR 
of Notch pathway. (G, H) HEY2 immunohistochemistry. (I) RT-qPCR of TGF-β1. (J, K) 
Phospho-SMAD2 (Ser465, Ser467) immunohistochemistry. (L) RT-qPCR of EGFR. (M, N) 
Phospho-AKT (Ser473) immunohistochemistry. Nuclei were counterstained with 
Hematoxylin. Scale bars: 100 μm. Control, n≥3; Mutant, n≥3 for immunohistochemistry 
and Control, n=6; Mutant, n=5 for RT-qPCR. *P<0.05; **P<0.01; ***P<0.001.  
 
Figure 7. Ductal deletion of Hnf1b leads to pancreatic intraepithelial neoplasia 
(PanIN) by 2 months. (A) H&E staining of mutant pancreata showing epithelial 
structures composed of columnar cells with abundant supranuclear cytoplasm and 
basally located nuclei. (B) Alcian blue staining. Columnar mutant epithelial cells 
revealed blue stained supranuclear mucin. (C) PanIN marker Claudin18 (brown) 
immunohistochemistry. (D) Sox9 (red) and GFP (green) immunostaining. Sox9+ ADM 
structures did not derived from Hnf1b-targeted GFP+ cells. (E) Quantification of the 














(n=6). Scale bars: 100 μm. (Control, n≥3; Mutant, n≥3 for histology and 
immunohistochemistry).  
 
Figure 8. Ductal deletion of Hnf1b promotes PanIN progression in a Kras activated 
context. Sox9-CreER;Hnf1bfl/fl Mutants were crossed with Elas-tTA; TetO-Flpase; 
KrasG12V mice (referred to as Kras) to obtain Sox9-CreER;Hnf1bfl/fl;Elas-tTA; TetO-Flpase; 
KrasG12V (referred to as Mutant;Kras) that combined perinatal inactivation of Hnf1b in 
ducts and oncogenic activation of KrasG12V in acinar cells. Analyses of the pancreata were 
performed at 5 months. (A) H&E staining. (B) Alcian Blue staining. (C) Claudin18 
(brown) immunostaining. (D) Quantification of the surface of the lesions stained with 
Alcian Blue. (E) Quantification of the number of lesions per cm2.  (F) Quantification of 
the size of the lesions. (G-K) High grade PanINs in Mutant;Kras by H&E staining (G-J) and 
Alcian Blue staining (K). Some lesions present marked cytological and architectural 
atypia with the formation of branching papillae. Nuclei are enlarged and hyperchromatic 
with focal nuclear stratification. Scale bars: 100μm. Mutants n=5, Kras n=4, Mutant;Kras 
n= 3. *P<0.05; ***P<0.001. 
 
Figure 9. Adult Hnf1b inactivation in ductal cells does not lead to obvious 
perturbation of acinar homeostasis. Tamoxifen was injected to 6-weeks old adult 
mice and analyses were performed at 2 months (A, B) or 5 months (C-F). (A) Mouse 
weight, pancreas weight and relative pancreas weight/body weight of 2-months old 
mice. (B) RT-qPCR of acinar markers at 2 months. (C) Mouse weight, pancreas weight 
and relative pancreas weight/body weight of 5-months old mice. (D) RT-qPCR of acinar 
markers at 5 months. (E, F) H&E staining of the pancreata at 5 months. Scale bars: 















Figure 10. Adult Hnf1b inactivation in ductal cells  leads to impaired acinar 
regeneration and to neoplasia following cerulein-induced pancreatitis. (A) 
Analysis of Hnf1b inactivation efficiency by RT-qPCR. (B) RT-qPCR of Amylase at D0, D3 
and D7. (C) RT-qPCR of acinar markers at D7. (D) RT-qPCR of inflammatory markers at 
D7. (E) H&E and Masson’s Trichrome stainings (F, G) Amylase (green) and Sox9 (red) 
immunostaining showing widespread ADM at D7 in mutants. (H-I) H&E staining, (J, K) 
Alcian blue staining, (L, M) Claudin18 (brown) immunostaining, showing PanIN in 
mutants. Scale bars: (E) 50 μm; (F-M) 100 μm. Control, n≥5; Mutants, n≥5 for RT-qPCR 















Antigen Host Dilution Reference
Amylase Goat 1/50 Santa Cruz;  sc-12821
Acetylated α-Tubulin Mouse 1/300 Sigma; T6793
AKT-Phospho-S473 Mouse 1/100 Proteintech; 66444-1-Ig
Arl13b Mouse 1/100 Antibodies Incorporated; 75-287
β-Catenin Mouse 1/100 BD Biosciences;  610153
Claudin-18 Rabbit 1/250 ThermoFisher Scientific; 700178
CTGF Rabbit 1/3000 Antibody Verify; AAS91519C
F4/80 Rat 1/500 BioLegend; 123102
Fabp4 Rabbit 1/200 Abcam; ab13979
GFP Chicken 1/400 Aves Labs; GFP-1020
Hey2 Rabbit 1/100 Proteintech; 10597-1-AP
Hnf1b Rabbit 1/50 Santa Cruz; sc-22840
Hnf6 Guinea pig 1/500 From Frederic Lemaigre's lab
Muc1 Hamster 1/100 ThermoFisher Scientific; HM-1630-PO
α-Smooth Muscle Actin Mouse 1/50 Sigma; C6198
Pan-CK Mouse 1/100 Sigma; C1801
Phospho-Histone H3 Mouse 1/300 Cell Signaling; 9706
Phospho-SMAD2 (Ser435, Ser 467) Rabbit 1/150 ThermoFisher Scientific; 44-244G 
PKCzeta Rabbit 1/500 Santa Cruz; sc-216
Sox9 Rabbit 1/100 Millipore; AB5535
SPP1/ Osteopontin Goat 1/100 R&D Systems; AF808
Vimentin Goat 1/100 Santa Cruz; sc-7557





















CPA CAACCCCTGCTCAGAAACTTACC TGGACTTGACCTCCACTTCAGA 
CTGF GCCAACCGCAAGATCGGAGTGT ACGGCCCCATCCAGGCAA
CXCL10 GCTGCCGTCATTTTCTGC TCTCACTGGCCCGTCATC























Prox1 CGC GAAGGACTCTCTTTGTC GATTGGGTGATAGCCCTTCAT
Ptf1a TTCCTGAAGCACCTTTGACAGA ACGGAGTTTCCTGGACAGAGT
Rbpj GTTTTGGCGAGAGTTTGTGGAAGAT TGGAGGCCGCTCACCAAACT
SMA GACGCTGCTCCAGCTATGT AGTTGGTGATGATGCCGTGT
Sox9 AAGCCGACTCCCCACATTCCTC CGCCCCTCTCGCTTCAGATCAA
Spp1 CCCTCCCGGTGAAAGTGACTGA GCACCAGCCATGTGGCTATAGG
TGF-b1 AGAGGTCACCCGCGTGCTAAT GGGCACTGCTTCCCGAATGTC
Vimentin GGGAGAAATTGCAGGAGGAG ATTCCACTTTGCGTTCAAGG
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